A perspective on HPK1 as a novel immuno-oncology drug target
In this perspective review, the role Hematopoietic Progenitor Kinase 1 (HPK1) in tumor immunity will be reviewed, with special emphasis on how T cells are negatively-regulated at different junctures of cancer-immunity cycle by this regulatory kinase. The review will highlight the strengths and weakn...
Main Authors: | Sansana Sawasdikosol, Steven Burakoff |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2020-09-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/55122 |
Similar Items
-
Immune landscape and biomarkers for immuno-oncology in colorectal cancers
by: Jeong Mo Bae, et al.
Published: (2020-09-01) -
Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology
by: Hae Woong Choi, et al.
Published: (2021-10-01) -
A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies
by: Tyler J. Nielsen, et al.
Published: (2021-03-01) -
Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo
by: Gitte Holmen Olofsson, et al.
Published: (2020-05-01) -
The Role of PRMT5 in Immuno-Oncology
by: Yoshinori Abe, et al.
Published: (2023-03-01)